Results 71 to 80 of about 908,554 (203)

Generating in vitro models of NTRK-fusion mesenchymal neoplasia as tools for investigating kinase oncogenic activation and response to targeted therapy

Oncogenesis, 2023
The discovery of neurotrophic tyrosine receptor kinase (NTRK) gene fusions as pan-tumor oncogenic drivers has led to new personalized therapies in oncology.
Fabio Vanoli, Laurie Herviou, Yusuke Tsuda, Patricia Sung, Ziyu Xie, Eve Fishinevich, Soe S. Min, William Mallen, Henry de Traux de Wardin, Yanming Zhang, Maria Jasin, Cristina R. Antonescu   +11 more
doaj   +1 more source

Identification of Trim24 as a new NTRK3 fusion partner in lung adenocarcinoma: Diagnostic challenges of a novel fusion

Human Pathology Reports, 2022
Reliable neurotrophin kinase (NTRK) fusion assessment is of special relevance since durable responses to targeted therapies have been observed regardless tumor type, NTRK gene or fusion partner.
Almudena Santón, Eugenia Olmedo, Tamara Caniego-Casas, Amparo Benito, Mónica García-Cosío, Jorge Esteban-Villarrubia, Pilar Garrido, José Palacios   +7 more
doaj   +1 more source

Estimating the Prognostic Value of the NTRK Fusion Biomarker for Comparative Effectiveness Research in The Netherlands [PDF]

Objectives: We evaluated the prognostic value of the neurotrophic tyrosine receptor kinase (NTRK) gene fusions by comparing the survival of patients with NTRK+ tumours with patients without NTRK+ tumours.
A Huygens, Simone, Dinjens, Winand N.M., M Versteegh, Matthijs, Mölken, Maureen Rutten van, Santi, Irene, Vellekoop, Heleen   +5 more
core   +4 more sources

Tester for deteksjon av NTRK genfusjoner hos pasienter med lokalavanserte eller metastatiske solide svulster. En metodevurdering. [PDF]

, 2022
Key messages The Norwegian Institute of Public Health has been commissioned to assess molecular tests for the identification of NTRK gene fusions in locally advanced or metastatic solid tumours.
Bidonde Torre, Maria Julia, Flodgren, Gerd Monika, Hamidi Ashtiani, Vida, Meneses Echavez, Jose Francisco   +3 more
core  

Pursuit of Gene Fusions in Daily Practice: Evidence from Real-World Data in Wild-Type and Microsatellite Instable Patients [PDF]

, 2021
Agnostic biomarkers such as gene fusions allow to address cancer patients to targeted therapies; however, the low prevalence of these alterations across common malignancies poses challenges and needs a feasible and sensitive diagnostic process. RNA-based
Aglietta, Massimo, Annaratone, Laura, Berrino, Enrico, Bragoni, Alberto, Carnevale-Schianca, Fabrizio, Casorzo, Laura, Fenocchio, Elisabetta, Garetto, Lucia, Marchiò, Sapino, Anna, Sarotto, Ivana, Venesio, Tiziana   +11 more
core   +1 more source

TRK fusion positive cancers:From first clinical data of a TRK inhibitor to future directions [PDF]

, 2020
Genetic alterations of neurotrophic tropomyosin or tyrosine receptor kinase (NTRK) 1/2/3 genes generate TRK fusion proteins have been reported in a variety of adult and child cancers from diverse cell/tissue lineages. Larotrectinib, a tumour-agnostic TRK
D'Angelo, Alberto, De Logu, Francesco, Massi, Daniela, Mini, Enrico, Nobili, Stefania, Roviello, Giandomenico, Sciortino, Marianna   +6 more
core   +3 more sources

Unclassified mesenchymal sarcoma with NTRK1-KHDRBS1 gene fusion: a case report of long-term tumor-free survival with crizotinib treatment

World Journal of Surgical Oncology, 2021
Background Mesenchymal sarcomas are tumors that originate from mesenchymal tissue. Most mesenchymal sarcomas can be accurately classified, but some are unclassifiable in clinical practice.
Weijie Chen, Huimei Wang, Dongxian Jiang, Lijuan Luan, Yuhong Zhou, Yingyong Hou   +5 more
doaj   +1 more source

Resolution on the results of Advisory Board “Searching the effective methods of testing and treating patients with NSCLC caused by NTRK gene fusions“

Медицинский совет, 2022
The Advisory Board was held on December 24, 2021. The molecular genetic research lead specialists and national lead oncologists discussed issues of diagnosis of NTRK gene translocations in patients with non-small cell lung cancer (NSCLC), as well as ...
E. V. Artamonova, V. V. Breder, L. Yu. Vladimirova, I. A. Demidova, E. N. Imyanitov, К. К. Laktionov, M. P. Matrosova, S. V. Orlov, E. О. Rodionov, D. D. Sakaeva, M. I. Sekacheva, A. V. Smolin, N. V. Fadeeva, M. L. Filipenko   +13 more
doaj   +1 more source

Non-random aneuploidy specifies subgroups of pilocytic astrocytoma and correlates with older age [PDF]

, 2015
Pilocytic astrocytoma (PA) is the most common brain tumor in children but is rare in adults, and hence poorly studied in this age group. We investigated 222 PA and report increased aneuploidy in older patients.
Amon, Baker, Barnholtz-Sloan, Barnholtz-Sloan, Chun, Chun, Chun, Cleveland, Collins, Collins, Collins, Compton, Cotman, Coyle, Cui, Di Agostino, Eischen, Eischen, Fletcher, Gandolfi, Gray, Gronych, Grundy, Guadagno, Guadagno, Gutmann, Gutmann, Hasselblatt, Hawkins, Hoffmann, Hoffmann, Hoffmann, Hoffmann, Huether, Jones, Kleihues, Kruchko, Lee, Levine, Li, Liu, Lozano, Lozano, Manfredi, Montagna, Montagna, Paulus, Pekrun, Pellman, Pfister, Prados, Puduvalli, Reifenberger, Rhee, Van den Berghe, Zlotnik   +55 more
core   +5 more sources

Oncogenic fusions: Targeting NTRK

Critical Reviews in Oncology/Hematology
Non-Small Cell Lung Cancer (NSCLC) is responsible for the highest number of cancer-related deaths in the United States. Thankfully, advancements in the detection and targeting of gene mutations have greatly improved outcomes for many patients. One significant mutation driving oncogenesis in various cancers, including NSCLC, is the neurotrophic tyrosine
Garo Hagopian, Misako Nagasaka
openaire   +2 more sources